利培酮联合氯氮平在长住院精神分裂症的随机对照研究

目的:探讨利培酮联合氯氮平治疗精神分裂症的疗效和安全性。方法:200例长住院符合国际疾病分类第10版(ICD-10)诊断标准的精神分裂症患者随机分为利培酮联合氯氮平组(简称联合组,N=90)和单用利培酮组(简称单用组,N=110),采用简明精神病量表(The brief psychiatric rating scale,BPRS)及阳性和阴性症状量表(the Positive and Negative Syndrome Scale,PANSS)评定疗效,采用治疗中需处理的不良反应症状量表(Treatment Emergent Symptoms Scale,TESS)评定安全性。结果:联合组的显效率高于单用组(84.44%vs.64.54%,P<0.05);两组治疗后BPRS、PANSS评分均低于治疗前如,联合组BPRS评分(23.02±6.26)vs.(45.01±5.78),PANSS评分(54.42±10.11)vs.(84.71±10.31),P<0.05;单用组BPRS评分(25.86±6.59)vs.(44.78±5.47),PANSS评分(57.70±10.15)vs.(85.96±10.13),P<0.05];治疗后,联合组BPRS、PANSS评分低于单用组如,BPRS评分联合组(23.02±6.26)vs.单用组(25.86±6.59),PANSS评分联合组(55.42±10.11)vs.单用组(57.70±10.15),P<0.05]。两组TESS评分在治疗后差异无统计学意义(P>0.05)。结论:利培酮联合氯氮平治疗精神分裂症可提高疗效,安全性较高,是一种值得借鉴的策略。

A Randomized Controlled Trial of Risperidone Combining with Clozapine in Treatment of the Schizophrenic With Long Hospitalization

Objective: To investigate the efficacy and safety of risperidone combining with clozapinc in the treatment of the schizophrenic with long hospitalization.Methods: Two hundred schizophrenic who met the criteria for schizophrenic in International Classification of Diseases(ICD-10) were randomly assigned to two groups.One group was treated with risperidone combining with clozapine and the other with risperidone only.The efficacy was measured with the brief psychiatric rating scale(BPRS) and the positive and negative syndrome scale(PANSS).The side effects were assessed with the treatment emergent symptoms scale(TESS).Results: At end point the significant improvement rate in the combining group was higher than that in the risperidone group.In all patients,the BPRS score and PANSS score were decreased after treatment.There were significant differences between the two groups(P<0.05).There were no significant differences between the two groups in the TESS score.Conclusion: The therapy of risperidone combing with clozapine has been found to be effective and well-tolerated approach in patients with schizophrenic.